Maternal use of psychostimulants for attention-deficit/hyperactivity disorder during pregnancy appears to only slightly increase the relative risk of pre-eclampsia and preterm birth, according to a population-based cohort study.
The oral pill fingolimod significantly reduces relapses vs interferon beta-1a in PARADIGMS, the first randomized controlled trial of fingolimod vs interferon beta-1a in paediatric multiple sclerosis (MS).
Some patients still do not feel comfortable with the magnetic resonance (MR) environment, and changing patient positioning (ie, feet-in first) does not necessarily help in minimizing claustrophobia, suggests a Singapore study.
Traumatic brain injury, which is signalled by more than one concussion diagnosis, during adolescence presents an increased risk of developing multiple sclerosis, a study suggests. This increased MS risk may be attributed to the initiation of an autoimmune process in the central nervous system.
At least 2 months of breastfeeding may cut the risk of sudden infant death syndrome (SIDS) by half, with the protective benefit increasing as the duration increases and achieved regardless of breastfeeding patterns, a study has found.
Ozanimod ─ a novel selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator ─ led to greater reduction in relapse rate and brain atrophy in patients with relapsing multiple sclerosis (MS) in a head-to-head comparison with the first-line treatment interferon β-1a (IFN), according to the SUNBEAM and RADIANCE trials presented at the ECTRIMS-ACTRIMS Meeting 2017 held in Paris, France.
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.